← Back to Search

Incentive-Based Intervention for Substance Abuse Disorders

Phase 2
Recruiting
Led By Mindy Waite, PhD
Research Sponsored by Aurora Health Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment
Age at least 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether offering people with substance abuse disorders incentive payments for healthy behaviors helps them combat their addiction.

Who is the study for?
This trial is for adults over 18 who have used opioids, cocaine, or methamphetamine non-medically in the last 21 days. Participants must be currently receiving some form of substance abuse treatment and meet specific medical criteria for substance use disorders. They need to have a smartphone with a data plan, an email they can access on their phone, and be willing to download and use the DynamiCare app.
What is being tested?
The study tests two incentive-based approaches using an app called DynamiCare to promote abstinence from drug use among individuals with opioid or cocaine addiction. One approach increases rewards over time (escalating), while the other decreases them (de-escalating) as participants demonstrate continued abstinence.
What are the potential side effects?
Since this trial involves behavioral interventions through an app rather than medications, there are no direct physical side effects like those associated with drugs. However, participants may experience psychological effects related to changes in behavior due to the incentives.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am currently in a substance abuse treatment program.
Select...
I am 18 years old or older.
Select...
I have a smartphone with a data plan and can download the DynamiCare app.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Abstinence from Opioid and/or Cocaine Use
Secondary study objectives
Negative Saliva Analysis Frequency
Negative Urinalysis Frequency
Psychotherapy Completion

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

7Treatment groups
Experimental Treatment
Active Control
Group I: Escalating LowExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and "reset" to the lowest amount when a test is positive or missed. The "Low" group will receive incentives worth $2-$8.
Group II: Escalating HighExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and "reset" to the lowest amount when a test is positive or missed. The "High" group will receive incentives worth $4-$16.
Group III: De-Escalating LowExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The "Low" group will receive incentives worth $6-12.
Group IV: De-Escalating HighExperimental Treatment1 Intervention
Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The "High" group will receive incentives worth $10-$20.
Group V: Constant LowExperimental Treatment1 Intervention
In the Constant groups, incentive amounts will remain unchanged across time. The "Low" group will receive incentives worth $8 every test.
Group VI: Constant HighExperimental Treatment1 Intervention
In the Constant groups, incentive amounts will remain unchanged across time. The "High" group will receive incentives worth $16.
Group VII: ControlActive Control1 Intervention
Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.

Find a Location

Who is running the clinical trial?

Aurora Health CareLead Sponsor
45 Previous Clinical Trials
15,818 Total Patients Enrolled
University of ChicagoOTHER
1,056 Previous Clinical Trials
760,309 Total Patients Enrolled
University of California, Santa CruzOTHER
4 Previous Clinical Trials
1,521 Total Patients Enrolled

Media Library

App-Based Contingency Management Clinical Trial Eligibility Overview. Trial Name: NCT04927143 — Phase 2
Opioid Use Disorder Research Study Groups: Constant Low, De-Escalating High, Escalating High, De-Escalating Low, Control, Escalating Low, Constant High
Opioid Use Disorder Clinical Trial 2023: App-Based Contingency Management Highlights & Side Effects. Trial Name: NCT04927143 — Phase 2
App-Based Contingency Management 2023 Treatment Timeline for Medical Study. Trial Name: NCT04927143 — Phase 2
Opioid Use Disorder Patient Testimony for trial: Trial Name: NCT04927143 — Phase 2
~144 spots leftby Nov 2025